Return to content in this issue

 

Seasonal administration of omalizumab in patients with uncontrolled asthma and sensitization to olive pollen

Serrano P1,2,3, Navas A1,2,3, Ruiz-León B*1,2,3, Herrero L4, Rondón C3,5, Jurado A1,2,3, Moreno-Aguilar C1,2,3

1Department of Immunology and Allergy, Reina Sofia University Hospital, Cordoba, Spain.
2Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/Reina Sofia University Hospital/University of Cordoba, Cordoba, Spain.
3National Network ARADyAL, Carlos III Health Institute, Madrid, Spain.
4Department of Information, Computer Systems and Archives Systems (Contabilidad Analítica), Hospital Infanta Margarita, Cabra, Córdoba, Spain.
5Biomedical Research Institute of Málaga (IBIMA)/ Allergy Unit Hospital Regional Universitario de Malaga, Spain.
*All authors have made a substantial contribution to the work, drafted the work and given their final approval.

J Investig Allergol Clin Immunol 2021; Vol. 31(5)
doi: 10.18176/jiaci.0657

Key words: Asthma, Omalizumab, Olive pollen, Seasonal